DarioHealth Corp [DRIO] stock is trading at $0.72, up 3.01%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DRIO shares have gain 12.64% over the last week, with a monthly amount glided 10.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
DarioHealth Corp [NASDAQ: DRIO] stock has seen the most recent analyst activity on January 29, 2025, when TD Cowen downgraded its rating to a Hold and also revised its price target to $1 from $2. Previously, Alliance Global Partners upgraded its rating to Buy on May 13, 2022, and kept the price target unchanged to $8.75. On April 22, 2021, Cowen initiated with a Outperform rating and assigned a price target of $31 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $30 on March 23, 2021. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $35 as its price target on February 25, 2021. Alliance Global Partners downgraded its rating to Neutral for this stock on February 01, 2021, and upped its price target to $22.25. In a note dated August 17, 2020, Aegis Capital initiated an Buy rating and provided a target price of $25 on this stock.
DarioHealth Corp [DRIO] stock has fluctuated between $0.56 and $2.60 over the past year. Currently, Wall Street analysts expect the stock to reach $10.75 within the next 12 months. DarioHealth Corp [NASDAQ: DRIO] shares were valued at $0.72 at the most recent close of the market. An investor can expect a potential return of 1393.06% based on the average DRIO price forecast.
Analyzing the DRIO fundamentals
DarioHealth Corp [NASDAQ:DRIO] reported sales of 23.05M for the trailing twelve months, which represents a growth of 111.00%. Gross Profit Margin for this corporation currently stands at 0.4% with Operating Profit Margin at -2.58%, Pretax Profit Margin comes in at -0.97%, and Net Profit Margin reading is -1.5%. To continue investigating profitability, this company’s Return on Assets is posted at -0.31, Equity is -0.53 and Total Capital is -0.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.52.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.6587 points at the first support level, and at 0.5965 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7616, and for the 2nd resistance point, it is at 0.8023.
Ratios To Look Out For
For context, DarioHealth Corp’s Current Ratio is 1.57. Also, the Quick Ratio is 1.32, while the Cash Ratio stands at 0.82. Considering the valuation of this stock, the price to sales ratio is 1.20, the price to book ratio is 0.39.
Transactions by insiders
Recent insider trading involved Nelson Steven Charles, Chief Commercial Officer, that happened on Nov 12 ’24 when 5000.0 shares were purchased. Chief Commercial Officer, Nelson Steven Charles completed a deal on Sep 10 ’24 to buy 5000.0 shares. Meanwhile, Chief Commercial Officer Nelson Steven Charles bought 5000.0 shares on Sep 11 ’24.
